Blurbs

H.C. Wainwright Sticks to Its Buy Rating for Zentalis Pharmaceuticals (ZNTL)

In a report released today, Andrew Fein from H.C. Wainwright reiterated a Buy rating on Zentalis Pharmaceuticals (ZNTLResearch Report), with a price target of $55.00. The company’s shares closed yesterday at $30.41.

Fein covers the Healthcare sector, focusing on stocks such as Sutro Biopharma, Amylyx Pharmaceuticals Inc, and ACADIA Pharmaceuticals. According to TipRanks, Fein has an average return of -7.5% and a 38.74% success rate on recommended stocks.

The word on The Street in general, suggests a Strong Buy analyst consensus rating for Zentalis Pharmaceuticals with a $64.00 average price target, an 110.46% upside from current levels. In a report released on July 29, Stifel Nicolaus also maintained a Buy rating on the stock with a $70.00 price target.

See the top stocks recommended by analysts >>

ZNTL market cap is currently $1.7B and has a P/E ratio of (7.89).

TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.

Zentalis Pharmaceuticals LLC is a clinical-stage biopharmaceutical company focused on discovering and developing small molecule therapeutics targeting fundamental biological pathways of cancers. It uses drug discovery engine, which it refers to as Integrated Discovery Engine, to identify targets and develop small molecule new chemical entities, or NCEs, with properties that it believes could result in potentially differentiated product profiles. The company’s product candidate, ZN-c5, is an oral selective estrogen receptor degrader, or SERD, currently in a Phase 1/2 clinical trial for the treatment of estrogen receptor positive, human epidermal growth factor receptor 2-negative, or ER+/HER2-, advanced or metastatic breast cancer. Its other products include ZN-c3, ZN-d5, and ZN-e4.

Read More on ZNTL:

Tired of arriving late to the Big Returns Party?​
Most investors don’t have major gainers like TSLA or NVDA on their radar from the start.
The profusion of opinions on social media and financial blogs makes it impossible to distinguish between real growth potential and pure hype.
​​For the past decade, we have developed and perfected technology designed to help private investors, just like you, find the best opportunities, with the greatest upside potential, in any financial climate.​
Learn More

Latest News Feed